Systemic inflammation is a low-grade immune alarm that runs through the whole body and never fully shuts off. It matters for nerve pain because its chemical signals, cytokines and chemokines, sensitize pain fibers and keep them firing, while the same signals inflame the walls of your arteries. A blood test called high-sensitivity CRP gives a rough reading of how loud the alarm is.
Inflammation is supposed to be a fire drill: loud, short, then over. On October 11, a hit-and-run driver broke my ankle and two ribs on a highway shoulder. The swelling that followed was inflammation doing its job, on its own schedule, which is what acute inflammation is for. The kind that hurts neuropathy patients is different. It never gets the all-clear, so it never stops.
What is the difference between healing inflammation and systemic inflammation?
Healing inflammation is local and temporary. White cells rush to an injury, clean it up and leave. Systemic inflammation is diffuse and chronic. Nothing is injured in one spot, yet immune signals stay elevated in the blood for years.
The main source is metabolic. Immune defense and energy handling are wired together at the cellular level, and chronic nutrient overload switches on a sterile, smoldering immune response inside fat, liver and muscle. The research name for it is metaflammation [1]. Its biggest factory is visceral fat, the fat packed around the organs, which the Obesity Medicine Association now calls “sick fat disease,” or adiposopathy [2].
It is not rare. Under 7 percent of US adults had optimal cardiometabolic health by NHANES 2017-2018 [3], down from under 12.2 percent who were metabolically healthy by NHANES 2009-2016 criteria [4]. Among our own chronic pain patients, fewer than 1 percent are metabolically healthy. Those are practice-reported figures from our own population, not trial outcomes, and individual results vary.
How does inflammation cause nerve pain?
Inflammation releases cytokines, chemokines and lipid mediators. Those chemicals sensitize and directly stimulate nociceptors, the pain-sensing fibers, along with the spinal cord neurons they connect to. Kept up long enough, they drive lasting changes in the pain pathway that sustain neuropathic pain after the original injury is gone [5].
In practice, that looks like three things that keep a damaged nerve hurting: inflamed tissue around the nerve, small C-fibers that fire with nothing touching the skin, and a dorsal root ganglion, the relay beside the spine, that has turned the volume up. Body-wide inflammation feeds all three. It is why a foot can burn at 2 a.m. while the sheet is the only thing touching it.
Can inflammation damage nerves before diabetes shows up?
The evidence says it can contribute. In a German cohort of 513 adults aged 62 to 81, followed for 6.5 years, 127 developed distal sensorimotor polyneuropathy. Compared with a normal weight, overweight carried about 3 times the odds and obesity about 3.5 times the odds. Every 5 cm of extra waist raised the odds by 22 percent. The link was the same in people with and without diabetes [6].
The researchers then asked what carried the effect. Two inflammatory chemokines, CCL7 and CXCL10, and one nerve-specific marker each explained up to 11 percent of the link between body fat and new neuropathy [6]. That is a real share, and it is not the whole story. Inflammation is one engine. Insulin, sugar by-products, vitamin status and nerve compression are others, which is why one test never closes the workup. More on the weight side is in obesity and neuropathy.
Is inflammation a cause of heart disease or just a marker?
For years, the answer was “probably a marker.” The CANTOS trial changed that. It enrolled 10,061 people with a prior heart attack and a high-sensitivity CRP of at least 2 mg/L, and gave them canakinumab, an antibody that blocks one inflammatory signal (interleukin-1β), or placebo [7].
Canakinumab did not lower cholesterol at all. It lowered CRP, and at the 150 mg dose it cut heart attack, stroke and cardiovascular death by 15 percent (hazard ratio 0.85) over a median of 3.7 years. It also raised fatal infections, and deaths from all causes did not differ [7].
Both halves of that result matter. Turning down inflammation alone protected the arteries, so inflammation is part of the cause. And shutting off one immune signal with a drug carried its own cost. The better target is the source: the sick fat and insulin that keep the alarm ringing.
How do I know if I have systemic inflammation?
High-sensitivity CRP is the standard reading. The CDC and American Heart Association bands are under 1 mg/L for lower cardiovascular risk, 1 to 3 for average, and above 3 for higher risk [8]. A reading above 10 usually means an infection or injury, and the test is repeated once you are well. Because one number wobbles, a second measurement a couple of weeks apart is more reliable than one.
CRP is a smoke detector, not a map. It tells you there is smoke. It does not tell you which room. That is why we read it beside insulin, LP-IR, GGT, oxidized LDL and the omega-3 index, the full list on neuropathy and heart disease.
What lowers systemic inflammation?
Less sick fat. In the STEP-HFpEF trial, 529 adults with obesity and heart failure with preserved ejection fraction took semaglutide or placebo for a year. The semaglutide group lost 13.3 percent of body weight against 2.6 percent, and their CRP fell 43.5 percent against 7.3 percent [9]. Shrink the factory and the output drops. GLP-1 medicines may be part of your solution, and they are chosen after the evaluation, not before it.
Different food. Refined grains and industrial seed oils keep insulin high and load cell membranes with oxidizable omega-6 fat. For our patients, who are already metabolically sick, the plate is built on protein, meat and fish, vegetables and real olive oil, with no refined grains.
Sleep and movement. Short, broken sleep worsens insulin resistance. Muscle that works pulls sugar from the blood with less insulin. Neither needs a gym: walking the distance your feet allow, every day, counts.
The environment around you. The cheapest calories in most neighborhoods are the most inflammatory ones, and long workdays and pain both push toward them. Naming that is not an excuse. It is the reason the plan has to be practical enough to survive a normal week.
Local work on the nerve. While the body-wide fire is coming down, the nerve does not have to wait. Our care calms inflammation around the nerve, quiets irritated C-fibers and settles the dorsal root ganglion. See regenerative neuropathy treatment. And if the belly fat will not budge, read why insulin keeps it there.
Inflammation you can measure is inflammation you can manage. Get the reading, find the source, and treat the source.
Questions patients ask about inflammation and nerve pain
If my CRP is normal, can inflammation still be causing my nerve pain?
Yes. CRP measures inflammation in the blood. Inflammation in the tissue around a nerve, or inside the dorsal root ganglion, can be active while the blood reading looks fine. A normal CRP lowers the odds of a body-wide problem; it does not rule out a local one.
Can inflammation cause neuropathy without diabetes?
It can contribute. In the German cohort above, the link between body fat and new neuropathy was the same in people with and without diabetes, and inflammatory chemokines carried part of it.
Sources
- Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177-185. doi:10.1038/nature21363 (PMID 28179656)
- Bays HE, Varney C, Alexander L, Ng J, Tondt J, Weber C, et al. Obesity and Cardiovascular Disease: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2026. Obes Pillars. 2026;20:100283. doi:10.1016/j.obpill.2026.100283 (PMID 42729919)
- O’Hearn M, Lauren BN, Wong JB, Kim DD, Mozaffarian D. Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018. J Am Coll Cardiol. 2022;80(2):138-151. doi:10.1016/j.jacc.2022.04.046 (PMID 35798448)
- Araújo J, Cai J, Stevens J. Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition Examination Survey 2009-2016. Metab Syndr Relat Disord. 2019;17(1):46-52. doi:10.1089/met.2018.0105 (PMID 30484738)
- Ellis A, Bennett DLH. Neuroinflammation and the generation of neuropathic pain. Br J Anaesth. 2013;111(1):26-37. doi:10.1093/bja/aet128 (PMID 23794642)
- Schlesinger S, Herder C, Kannenberg JM, Huth C, Carstensen-Kirberg M, Rathmann W, et al. General and Abdominal Obesity and Incident Distal Sensorimotor Polyneuropathy: Insights Into Inflammatory Biomarkers as Potential Mediators in the KORA F4/FF4 Cohort. Diabetes Care. 2019;42(2):240-247. doi:10.2337/dc18-1842 (PMID 30523031)
- Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914 (PMID 28845751)
- Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511. doi:10.1161/01.cir.0000052939.59093.45 (PMID 12551878)
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 (PMID 37622681)
